Kura Oncology (NASDAQ:KURA) Earns “Market Outperform” Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Thursday morning,Benzinga reports. They currently have a $28.00 target price on the stock.

KURA has been the subject of a number of other research reports. Wedbush boosted their price objective on Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a report on Thursday. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday. Scotiabank lowered their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Finally, HC Wainwright increased their price target on shares of Kura Oncology from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Trading Down 2.5 %

Shares of NASDAQ:KURA opened at $8.82 on Thursday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $6.98 and a twelve month high of $24.17. The company’s 50 day moving average is $8.79 and its 200 day moving average is $15.11.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same quarter in the previous year, the firm posted ($0.50) EPS. Analysts expect that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock valued at $100,739 over the last ninety days. Insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter worth $25,000. Point72 DIFC Ltd acquired a new position in shares of Kura Oncology in the 3rd quarter valued at $146,000. E Fund Management Co. Ltd. purchased a new position in shares of Kura Oncology during the 4th quarter worth $90,000. Erste Asset Management GmbH acquired a new stake in shares of Kura Oncology during the 3rd quarter worth about $215,000. Finally, Bellevue Group AG raised its holdings in Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.